Cargando…
Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids—What Is the Relationship?
Neuroendocrine tumors (NETs) throughout the body are the focus of much current interest. Most occur in the gastrointestinal tract and have shown a major increase in incidence over the past 30 years, roughly paralleling the world-wide increase in the use of proton pump inhibitor (PPI) drugs. The grea...
Autor principal: | McCarthy, Denis M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014182/ https://www.ncbi.nlm.nih.gov/pubmed/31963924 http://dx.doi.org/10.3390/ijms21020662 |
Ejemplares similares
-
Gastric Carcinoid with Hypergastrinemia: Report of Three Cases
por: Furumoto, Katsuyoshi, et al.
Publicado: (2010) -
Hypergastrinemia
por: Dacha, Sunil, et al.
Publicado: (2015) -
Hyperemesis-induced Wernicke-Korsakoff Syndrome due to Hypergastrinemia during Long-term Treatment with Proton Pump Inhibitors
por: Miyanaga, Rei, et al.
Publicado: (2020) -
Gastrin and the Moderate Hypergastrinemias
por: Rehfeld, Jens F.
Publicado: (2021) -
The consequences of hypergastrinemia.
por: Creutzfeldt, W.
Publicado: (1994)